Companies in #Diabetes

Abbott Laboratories is a global healthcare company that researches, develops, manufactures, and distributes a diverse portfolio of health solutions across medical devices, diagnostics, nutritional products, and established pharmaceuticals. Key products include FreeStyle Libre (CGM), Ensure/Similac (nutrition), Alinity (diagnostics), and MitraClip (structural heart).

Clinical-stage biopharmaceutical company spun out from Kura Oncology to develop small-molecule menin inhibitors as potentially disease-modifying therapies for diabetes and cardiometabolic diseases.

Curanex Pharmaceuticals is a developmental-stage pharmaceutical company discovering, developing, and commercializing botanical drugs for inflammatory and other serious diseases. Its lead candidate, Phyto-N, is being advanced across ulcerative colitis, atopic dermatitis, COVID-19, diabetes, nonalcoholic fatty liver disease, and gout, with a 2026 pipeline expansion into cancer cachexia and advanced cancer supportive care. The company completed GMP manufacturing and toxicology milestones supporting a planned Q4 2026 IND submission for ulcerative colitis. Curanex (formerly Fordman Pharma, renamed November 2023) listed on Nasdaq in August 2025 at $4.00 per share and implemented a 1-for-20 reverse stock split effective August 20, 2026 to maintain listing compliance, reducing shares outstanding to approximately 1.57 million.

Insulin management software company whose Glucommander platform provides cloud-based inpatient glycemic control and diabetes treatment optimization across the continuum of care.

Insulet Corporation is a medical device company best known for its Omnipod insulin management system, the only tubeless insulin pump available in the U.S. Insulet is expanding into adjacent chronic disease management through technology partnerships.

MannKind is a biopharmaceutical company focused on inhaled therapeutic products for endocrine and orphan lung diseases, built on its proprietary Technosphere dry-powder inhalation platform. Its commercial portfolio includes Afrezza, the only FDA-approved inhaled mealtime insulin, and the V-Go wearable insulin delivery device; the company also manufactures Tyvaso DPI, an inhaled treprostinil powder commercialized by United Therapeutics, from which MannKind earns royalties and manufacturing revenue, and it has expanded into heart-failure fluid management with FUROSCIX and its ReadyFlow autoinjector. The pipeline extends the same platform into interstitial lung disease with MNKD-201 (inhaled nintedanib), which reported positive Phase 1b data in 2026, and into metabolic disease through a September 2026 licensing and collaboration agreement with Rose Pharma for ROSE-010, an inhaled rapid-acting GLP-1 for weight management. Founded in February 1991 by Alfred E. Mann and headquartered in Danbury, Connecticut, the company reported second-quarter 2026 revenue of $109.4 million, up 43% year over year, at a gross margin above 79%, while still recording a small operating loss and negative free cash flow. A Phase 3 program in nontuberculous mycobacterial lung disease with nebulized clofazimine (MNKD-101) was discontinued for futility in November 2025, with the NTM effort redirected to an earlier dry-powder formulation.

Mitsubishi Tanabe Pharma is a Japanese pharmaceutical company with a portfolio spanning immunology, central nervous system disorders, diabetes, and vaccines. It is the originator of Radicava (edaravone) for ALS and has been divesting non-core plants as part of a post-buyout strategic pivot.

Novo Nordisk is a Danish multinational pharmaceutical company that discovers, develops, and markets therapies for diabetes, obesity, rare endocrine disorders, and other chronic diseases. The company is the world's largest insulin producer and a leading developer of GLP-1 receptor agonists for diabetes (Ozempic, Rybelsus) and obesity (Wegovy), with a deep pipeline in cardiometabolic and rare-disease therapeutics.

Sanofi (NASDAQ: SNY; Euronext: SAN) is a global biopharmaceutical company with major franchises in immunology (Dupixent, partnered with Regeneron), vaccines (Beyfortus, Fluzone, Dengvaxia), rare disease (Genzyme-legacy Pompe, Fabry, MS), and a growing oncology pipeline. Sanofi has been reshaping its R&D portfolio toward immunology and rare disease while spinning off its consumer health unit.